



N-terminus FITC labeling of peptides on solid support: the truth behind the spacer

Magali Jullian^b, Anaïs Hernandez^b, Amélie Maurras^b, Karine Puget^b,
Muriel Amblard^a, Jean Martinez^a, Gilles Subra^{a,*}

^a Institut des Biomolécules Max Mousseron UMR 5247, CNRS, universités Montpellier 1 et 2, 15 Avenue Charles Flahault BP 14491, 34093 Montpellier Cédex 5, France

^b Genepep ZA Les Baronnes, 34730 Prades le Lez, France

ARTICLE INFO

Article history:

Received 2 October 2008

Revised 28 October 2008

Accepted 29 October 2008

Available online 3 November 2008

Keywords:

FITC

Fluorescein isothiocyanate

Peptide labeling

SPPS

HMBA linker

Thiohydantoin

Peptide synthesis

Side reaction

ABSTRACT

Fluorescein isothiocyanate (FITC) is an amine reactive derivative of fluorescein dye that has wide ranging application in biochemistry. It has been extensively used to label peptides and proteins. However, its use in solid phase peptide synthesis is restricted. Indeed, in acidic conditions required for linker cleavage, N-ter FITC-labeled peptides undergo a cyclization leading to the formation of a fluorescein with subsequent removal of the last amino acid. This can be avoided when a spacer such as amino hexanoic acid is used or if non-acidic cleavage is operated to release targeted peptide from the resin.

© 2008 Elsevier Ltd. All rights reserved.

Fluorescent dyes are major tools for the labeling of biomolecules. Fluorescein derivatives are probably the most widely used of this kind of reagents displaying a wide range of applications in fluorescence microscopy,¹ flow cytometry,² and immunofluorescence-based³ assays. The fluorescein isothiocyanate (FITC) is more reactive than the carboxy fluorescein which, moreover, has to be activated before use. FITC was used extensively to react with sulfhydryl⁴ targeting reduced cysteine side chains and especially amino groups in peptides or proteins.⁵ For numerous applications, it is convenient to introduce fluorescent label during the chemical synthesis.^{6,7} FITC may react during the course of solid phase peptide synthesis, either with a lysine or an ornithine side chain after selective unmasking of protecting group⁸ or with a primary amino group at the N-terminal side of the growing peptide. In the latter case, an alkyl spacer such as aminohexanoic acid (Ahx) is introduced between the last amino acid and the thiourea linkage generated through the reaction of isothiocyanate and amine.⁹ This is traditionally justified to take away the bulky fluorescent dye from the bioactive sequence.

As part of a project that aimed to design new cell penetrating peptides, we synthesized a series of fluorescent peptides by Fmoc


SPPS. FITC was introduced at the N-terminal side of anchored peptides. In this strategy, we believed that a degradation could happen during TFA by a mechanism similar to Edman degradation induced by phenylthioisocyanate.¹⁰ The proposed mechanism is detailed in Scheme 1 and yields fluorescein thiohydantoin (FTH) **4**. A recent patent drew profit from this reaction in solution to propose a method for analyzing protein adducts.¹¹ It is worth noting that some FTH were already obtained in the late seventies from unprotected aminoacids or from albumin.¹²

In order to evaluate the importance of this side reaction on solid support, we performed a study on five model peptides (**1a–e**), which are synthesized on Fmoc-Rink amide PS resin (0.98 mol/g). After classical Fmoc-SPPS,¹³ an aliquot (≈10 mg) of each peptidyl-Rink amide PS resin **1a–e** was submitted to TFA/TIS/H₂O 95:2.5:2.5 for 2 h to check the purity of model peptides. After diethyl ether precipitation of crude peptides and lyophilization, LC/MS analyses showed that expected unprotected peptides **1'a–e** were obtained with good purity (Table 1).

Resins **1a–e** were then treated with FITC and DIEA in the dark for 2 h to yield supported compounds **2a–e**. At this stage, only DIEA and FITC used in excess were detected in coupling solution but no thiohydantoin **4a–e**. Moreover, Kaiser test¹⁴ performed on resin beads **2a–e** was negative, indicating the efficiency of isocyanate coupling on the primary amine. Then, resins **2a–e** were submitted

* Corresponding author. Tel.: +33 4 67 54 86 55; fax: +33 4 67 54 86 54.

E-mail address: gilles.subra@univ-montpl.fr (G. Subra).



Scheme 1.

Table 1

Model peptides 1'a–e in Scheme 1

Compound	Sequence and MW calc.	Ions detected (ESI+)	Purity ^a (%)
1'a	Neurokinine A H-HKTSFVGLM-NH ₂ 1132.6 Da	[M+H] ⁺ <i>m/z</i> = 1133.3; [M+2H] ²⁺ <i>m/z</i> = 516.7	99
1'b	Neurokinine B H-DMHDFVGLM-NH ₂ 1209.5 Da	[M+H] ⁺ <i>m/z</i> = 1210.5; [M+2H] ²⁺ <i>m/z</i> = 605.8	90 ^b
1'c	Fulicine H-FNEFV-NH ₂ 653.3 Da	[M+H] ⁺ <i>m/z</i> = 654.3; [M+2H] ²⁺ <i>m/z</i> = 319.3	96
1'd	Nle CCK ₄ H-W Nle DF-NH ₂ 578.4	[M+H] ⁺ <i>m/z</i> = 579.2	96
1'e	FLPAG peptide H-FLPAG-NH ₂ 502.3	[M+H] ⁺ <i>m/z</i> = 503.2; [2M+H] ⁺ <i>m/z</i> = 1005.6	97


^a Purity percent was estimated by integration of peak area in LC/MS chromatogram recorded at 214 nm.^b 10% of oxidation of methionine was detected.

Table 2

Cleavage products of resin 2a–e

Truncated peptide 3	MW calc.	Ions detected (ESI+)	Purity ^a (%)	Hydantoïne 4	MW calc.	Ions detected (ESI+)
3a, H-KTDSFVGLM-NH ₂	995.5	[M+H] ⁺ <i>m/z</i> = 996.7 [M+2H] ²⁺ <i>m/z</i> = 498.9	63 ^b	4a, R =	526.1	[M+H] ⁺ <i>m/z</i> = 527.2 [M+2H] ²⁺ <i>m/z</i> = 264.1
3b, H-MHDFVGLM-NH ₂	1094.5	[M+H] ⁺ <i>m/z</i> = 1095.4 [M+2H] ²⁺ <i>m/z</i> = 584.3	71 ^b	4b, R =	504.5	[M+H] ⁺ <i>m/z</i> = 505.1
3c, H-NEFV-NH ₂	506.3	[M+H] ⁺ <i>m/z</i> = 507.2 [2M+H] ⁺ <i>m/z</i> = 1013.7	96	4c, R =	536.1	[M+H] ⁺ <i>m/z</i> = 537.2
3d, H-Nle DF-NH ₂	392.2	[M+H] ⁺ <i>m/z</i> = 393.1 [2M+H] ⁺ <i>m/z</i> = 785.5	62	4d, R =	575.2	[M+H] ⁺ <i>m/z</i> = 576.2
3e, H-LPAG-NH ₂	355.2	[M+H] ⁺ <i>m/z</i> = 356.3	75	4e, R =	536.1	[M+H] ⁺ <i>m/z</i> = 537.1

^a Purity percent was estimated by integration of peak area in LC/MS chromatogram recorded at 214 nm. Yield ranged from 49% to 55% calculated on the basis of theoretical resin loading.^b 10–15% of oxidation of methionine was detected.



to TFA/TIS/H₂O treatment for 2 h. Thiohydantoin **4a–e** and truncated peptides **3a–e** were detected by LC/MS analysis of an aliquot of TFA cleavage solution (Scheme 1). We noticed that diethyl ether addition led to precipitation of truncated peptides **3a–e** (Table 2). Thiohydantoin **4a–e** were soluble in ether and after evaporation of the discarded diethylether phase, their presence was confirmed by LC/MS analysis.

The thiazolinone mechanism is driven by the formation of the five-membered cycle only possible when the last residue in the peptide sequence is an α -amino acid. To complete this study, peptidyl-resins **1a–e** were coupled with a ϵ -amino or a β -amino acid (Fmoc-Ahx-OH and Fmoc- β Ala-OH, respectively) and were reacted with FITC (Scheme 2). TFA-mediated cleavage afforded the expected fluorescent peptides **5a–e** and **6a–e**, respectively. After LC/MS analyses, no truncated peptides **3a–e** were detected, and the labeled peptides were obtained with high purity (Table 3)


Table 3
FITC-labeled peptides **5** and **6** (Scheme 2)

Compound	MW calc.	Ions detected (ESI ⁺)	Purity ^a (%)
5a	1593.6	[M+2H] ²⁺ m/z = 797.4 [M+3H] ³⁺ m/z = 532.17	99
5b	1669.6	[M+2H] ²⁺ m/z = 836.0 [M+3H] ³⁺ m/z = 557.7	63
5c	1113.4	[M+H] ⁺ m/z = 1114.5 [M+2H] ²⁺ m/z = 557.8	95
5d	1038.4	[M+H] ⁺ m/z = 1039.5 [M+2H] ²⁺ m/z = 520.4	95
5e	962.4	[M+H] ⁺ m/z = 963.5 [M+2H] ²⁺ m/z = 482.3	96
6a	1634.6	[M+2H] ²⁺ m/z = 818.7 [M+3H] ³⁺ m/z = 546.1	99
6b	1711.6	[M+H] ⁺ m/z = 857.0 [M+2H] ²⁺ m/z = 571.7	99
6c	1155.4	[M+H] ⁺ m/z = 1156.65 [M+2H] ²⁺ m/z = 578.9	97
6d	1080.4	[M+H] ⁺ m/z = 1081.5 [M+2H] ²⁺ m/z = 541.4	95
6e	1004.4	[M+H] ⁺ m/z = 1005.6 [M+2H] ²⁺ m/z = 503.4	96

^a Purity percent was estimated by integration of peak area in LC/MS chromatogram recorded at 214 nm.

and average yield of 55%. The alkylene spacer has no incidence on the coupling efficiency of FITC on the free amino group at the N terminus of supported peptides.

According to our observations, the removal of the last amino acid by thiohydantoin formation occurs during final TFA treatment. As an evidence, model peptide **1''e** (identical to **1'e**, previously obtained on Rink amide linker) was synthesized on hydroxymethyl benzamido-PS-resin (HMBA-PS 1.1 mmol/g) using Fmoc SPPS (Scheme 3). The use of the base-labile linker HMBA¹⁵ enabled to cleave the peptide from resin **7** using ammonia-saturated methanol solution for 4 h (purity = 81%, yield = 40%).¹⁶ Resin **7** reacted as usual with FITC and DIEA in the dark for 2 h to yield fluorescent-immobilized peptidyl-resin **8**.



TFA treatment performed on an aliquot (10 mg) of resin **8** led to a yellow TFA solution and white resin beads. After TFA evaporation and LC/MS analysis, fluorescent thiohydantoin **9** was detected as the main product and no peptide was released from the resin as expected. Ammonolysis of the same resin afforded expected fluorescent peptide **10** with 86% purity and 71% yield.

In conclusion, we highlighted a side reaction occurring upon TFA-mediated cleavage of N-terminal FITC-modified peptides on solid support. This reaction follows the Edman degradation pathway affording a fluorescent thiohydantoin (FTH) from the last α -amino acid of the peptide sequence. As expected, this reaction can be avoided by introduction of a non- α amino acid spacer between thiourea bond and the peptide or by using basic conditions for final deprotection of the FITC peptide from the resin. The steric hindrance considerations, sometimes considered as the main reason of using Ahx before fluorescent dye introduction, are not the reason why FITC should not be coupled directly on peptide.

Ahx or β Ala were used successfully as spacers to generate FITC-labeled peptides. We also demonstrated that fluorescein-NH-CS-peptides can be obtained using base-labile linker HMBA. It is obvious that this last method suffers consistent limitations as appropriate non-acid labile side chain protecting groups are required to avoid TFA treatment of FITC-labeled peptide.

References and notes

1. Haraguchi, T.; Shimi, T.; Koujin, T.; Hashiguchi, N.; Hiraoka, Y. *Genes Cells* **2002**, *7*, 881–887.
2. Deka, C.; Lehnert, B. E.; Lehnert, N. M.; Jones, G. M.; Sklar, L. A.; Steinkamp, J. A. *Cytometry* **1996**, *25*, 271–279.
3. Staines, W. A.; Meister, B.; Melander, T.; Nagy, J. I.; Hokfelt, T. *J. Histochem. Cytochem.* **1988**, *36*, 145–151.
4. Miki, M.; Dosremedios, C. G. *J. Biochem. Tokyo* **1988**, *104*, 232–235.
5. Boturn, D.; Coll, J.-L.; Garanger, E.; Favrot, M.-C.; Dumy, P. *J. Am. Chem. Soc.* **2004**, *126*, 5730–5739.
6. Carrigan, C. N.; Imperiali, B. *Anal. Biochem.* **2005**, *341*, 290–298.
7. Song, A.; Wang, X.; Zhang, J.; Marik, J.; Lebrilla, C. B.; Lam, K. S. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 161–165.
8. Park, S. I.; Renil, M.; Vikstrom, B.; Amro, N.; Song, L.-w.; Xu, B.-I.; Lam, K. S. *Lett. Pept. Sci.* **2002**, *8*, 171–178.
9. Zhai, D.; Jin, C.; Shiao, C.-w.; Kitada, S.; Satterthwait, A. C.; Reed, J. C. *Mol. Cancer Ther.* **2008**, *7*, 1639–1646.
10. Edman, P. V. *Nature* **1956**, *177*, 667–668.
11. Rydberg, P. WO Patent 101020, 2005.
12. Maeda, H.; Ishida, N.; Kawauchi, H.; Tuzimura, K. *J. Biochem.* **1969**, *65*, 777–783.
13. Amblard, M.; Fehrentz, J.-A.; Martinez, J.; Subra, G. *Mol. Biotech.* **2006**, *33*, 239–254.
14. Sarin, V. K.; Kent, S. B. H.; Tam, J. P.; Merrifield, R. B. *Anal. Biochem.* **1981**, *117*, 147–157.
15. Atherton, E.; Logan, C. J.; Sheppard, R. C. *J. Chem. Soc., Perkin Trans. 1* **1981**, 538–546.
16. 9% C-ter free acid peptide was detected by LC/MS as a result of hydrolysis of HMBA linker.